
Opinion|Videos|July 3, 2024
Gene Therapy for Treatment of Duchenne Muscular Dystrophy
Author(s)Emma Ciafaloni, MD
Focusing on gene therapy and exon skipping medications, an expert on Duchenne muscular dystrophy discusses current and emerging treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Provide an overview of delandistrogene moxeparvovec, micro-dystrophin gene therapy, that received accelerated approval for Duchenne muscular dystrophy (DMD) in 2023.
- Discuss ongoing studies for fordadistrogene movaparvovec gene therapy and other exon skipping therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Coordinating Multidisciplinary SMA Care in an Expanding Treatment Landscape
2
Tanruprubart Shows Rapid Responses in First FORWARD Cohort for Guillain-Barre Syndrome
3
Building a Multidisciplinary SMA Clinic: Lessons From 2 Decades of Practice
4
Bridging Pediatric and Adult Care in Spinal Muscular Atrophy
5











